U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07105059) titled 'A Study of Teclistamab and Mezigdomide in People With Multiple Myeloma' on July 29.
Brief Summary: The researchers are doing this study to find out whether combining teclistamab and mezigdomide is a safe and effective treatment approach in people with relapsed/refractory multiple myeloma (MM).
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Multiple Myeloma
Intervention:
DRUG: Teclistamab
After the priming, patients will start Teclistamab step up dosing. Mezigdomide will not be given during the Teclistamab step up. After the priming and step-up, patients will start combination treatment with Teclistamab and ...